Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03CNS
|
||||
| Former ID |
DAP000604
|
||||
| Drug Name |
Cyclothiazide
|
||||
| Synonyms |
Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H16ClN3O4S2
|
||||
| InChI |
InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
|
||||
| InChIKey |
BOCUKUHCLICSIY-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 2259-96-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
583075, 7413729, 7848319, 8149965, 8151863, 10514282, 11336079, 11361318, 11373658, 11462290, 11491865, 17404884, 24278350, 26751850, 29222063, 46508269, 47291198, 47589058, 47736553, 47810814, 48110509, 48415831, 49890386, 50104549, 50104550, 50328346, 53777427, 56424127, 57321515, 85085062, 85230990, 85787796, 90341445, 92303854, 92307849, 96079565, 99301992, 103124246, 103249003, 104075181, 104171141, 104301976, 117629245, 121361127, 124749619, 124801467, 124879795, 124886816, 127543751, 134221777
|
||||
| SuperDrug ATC ID |
C03AA09
|
||||
| SuperDrug CAS ID |
cas=000135079
|
||||
| Target and Pathway | |||||
| Target(s) | Carbonic anhydrase II | Target Info | Inhibitor | [537999] | |
| NetPath Pathway | IL4 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| References | |||||
| Ref 467506 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4167). | ||||
| Ref 538463 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 013157. | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.